Minireview: ribonucleic acid interference for the identification of new targets for the treatment of metabolic diseases.
Over the past years, RNA interference (RNAi) has exploded as a new approach to manipulate gene expression in mammalian systems. More recently, RNAi has acquired interest as a tool to identify new targets for therapeutic intervention. This review focuses on the current understanding of RNAi biology, how RNAi has been used to study the role of different genes in the pathogenesis of diabetes and obesity, and the use of RNAi screens for the identification of new targets for metabolic diseases. Also reviewed are the in vivo proof of principle experiments that provide the validation of these new targets for the development of RNAi-based therapeutics for diabetes.
Department Metabolic Diseases, Hoffmann-La Roche, Nutley, New Jersey 07110, USA. cristina.rondinone@roche.com
Cristina M
CM
Rondinone
D000256:Adenoviridae / Q000235:genetics; D054369:Agouti-Related Protein; D000818:Animals; D001055:Apolipoproteins B / Q000235:genetics; D003920:Diabetes Mellitus / Q000628:therapy*; D051766:Early Growth Response Protein 1 / Q000235:genetics; D006801:Humans; D007328:Insulin / Q000502:physiology; D055504:Insulin Receptor Substrate Proteins; D036341:Intercellular Signaling Peptides and Proteins; D009765:Obesity / Q000628:therapy*; D010750:Phosphoproteins / Q000235:genetics; D011506:Proteins / Q000235:genetics; D034622:RNA Interference; D015398:Signal Transduction; D014157:Transcription Factors / Q000235:genetics
D054369:Agouti-Related Protein; D001055:Apolipoproteins B; C497325:EGR1 protein, human; D051766:Early Growth Response Protein 1; C526292:IRS1 protein, human; D007328:Insulin; D055504:Insulin Receptor Substrate Proteins; D036341:Intercellular Signaling Peptides and Proteins; D010750:Phosphoproteins; D011506:Proteins; D014157:Transcription Factors; C111264:peroxisome-proliferator-activated receptor-gamma coactivator-1